For some, the dual-agonist mechanism of Mounjaro provides the perfect balance of efficacy and tolerability, while others may find the single-agonist Wegovy 7.2mg dose, introduced on January 12, 2026, more suitable for their specific metabolic architecture
What to Know About Weight Loss Drugs By Lizzie Streit, MS, RDN, LD Anti-obesity medications are getting more attention these days, especially with the Food and Drug Administrations (FDA) approval of semaglutide (Wegovy) for long-term use
No surgery
With L-Carnitine, the body shifts the focus to using stored fat as energy
Mechanisms In summary, pre-clinical studies of anti-inflammatory signalling and findings from and observational studies of clinical datasets suggest GLP-1 RAs may confer dual metabolic and disease-modifying advantages in IBD, particularly in people with obesity, but evidence from prospective trials is lacking [2]
Oil cysts (cystic collections of liquefied fat that didn't survive) can form in some cases